Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Silverback Therapeutics price target lowered to $5 from $6 at Stifel » 14:38
05/13/22
05/13
14:38
05/13/22
14:38
SBTX

Silverback Therapeutics

$2.97 /

-0.055 (-1.82%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey lowered the firm's price target on Silverback Therapeutics to $5 from $6 and keeps a Hold rating on the shares. The focus has shifted "squarely" to the prospects of SBT8230 following Silverback's discontinuation of its two lead oncology assets, said Willey, who thinks the extended timelines before there is more clarity is likely to keep shares in check despite what he notes is a current "sub-cash valuation."

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$2.97 /

-0.055 (-1.82%)

04/01/22 Goldman Sachs
Silverback Therapeutics downgraded to Neutral from Buy at Goldman Sachs
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 JonesTrading
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
SBTX Silverback Therapeutics
$2.97 /

-0.055 (-1.82%)

SBTX Silverback Therapeutics
$2.97 /

-0.055 (-1.82%)

Earnings
Silverback Therapeutics reports Q1 EPS (70c), consensus (54c) » 16:06
05/12/22
05/12
16:06
05/12/22
16:06
SBTX

Silverback Therapeutics

$2.98 /

+0.08 (+2.76%)

"In the first…

"In the first quarter of 2022, we have made significant progress in advancing the preclinical development of SBT8230, a first-in-class antibody-drug conjugate that we believe has the potential to drive functional cure in patients with chronic hepatitis B (cHBV) by eliciting a liver-localized anti-viral response," said Laura Shawver, Ph.D., CEO. "We believe that activating the immune response is an important component of a functional cure and may be combined with treatments that target the HBV life cycle to improve durability. Our team is on track to complete a regulatory submission in the fourth quarter of 2022, enabling the planned initiation of the single ascending dose healthy volunteer cohort of the Phase 1 study in the first quarter of 2023. We plan to report data from this cohort in the second half of 2023."

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$2.98 /

+0.08 (+2.76%)

04/01/22 Goldman Sachs
Silverback Therapeutics downgraded to Neutral from Buy at Goldman Sachs
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 JonesTrading
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
SBTX Silverback Therapeutics
$2.98 /

+0.08 (+2.76%)

SBTX Silverback Therapeutics
$2.98 /

+0.08 (+2.76%)

Over a month ago
Downgrade
Silverback Therapeutics downgraded to Neutral from Buy at Goldman Sachs » 16:44
04/01/22
04/01
16:44
04/01/22
16:44
SBTX

Silverback Therapeutics

$3.22 /

-0.22 (-6.40%)

Goldman Sachs analyst…

Goldman Sachs analyst Paul Choi downgraded Silverback Therapeutics to Neutral from Buy with a price target of $3.50, down from $25. Silverback reported Q4 earnings, and announced a major strategic change as the company has decided to discontinue its oncology programs, SBT6050 and SBT6290, "both of which represented the most advanced assets in the pipeline."

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.22 /

-0.22 (-6.40%)

04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 JonesTrading
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 H.C. Wainwright
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
SBTX Silverback Therapeutics
$3.22 /

-0.22 (-6.40%)

SBTX Silverback Therapeutics
$3.22 /

-0.22 (-6.40%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:34
04/01/22
04/01
09:34
04/01/22
09:34
WYNN

Wynn Resorts

$79.77 /

-1.34 (-1.65%)

, DELL

Dell Technologies

$50.18 /

-4.1 (-7.55%)

, IMRX

Immuneering

$6.47 /

-0.36 (-5.27%)

, POSH

Poshmark

$12.65 /

-0.69 (-5.17%)

, VRT

Vertiv Holdings

$14.00 /

+0.28 (+2.04%)

, BLND

Blend Labs

$5.68 /

-0.3 (-5.02%)

, UPST

Upstart

$109.00 /

-4.87 (-4.28%)

, GPS

Gap

$14.08 /

-0.56 (-3.83%)

, TELL

Tellurian

$5.30 /

-0.14 (-2.57%)

, CMA

Comerica

$90.42 /

-2.455 (-2.64%)

, CHKP

Check Point

$138.42 /

+0.04 (+0.03%)

, PARA

Paramount

$37.80 /

-0.315 (-0.83%)

, AWKNF

Awakn Life Sciences

$1.20 /

+ (+0.00%)

, SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

, W

Wayfair

$110.75 /

-10.75 (-8.85%)

Institutional investors…

ShowHide Related Items >><<
WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

W Wayfair
$110.75 /

-10.75 (-8.85%)

VRT Vertiv Holdings
$14.00 /

+0.28 (+2.04%)

UPST Upstart
$109.00 /

-4.87 (-4.28%)

TELL Tellurian
$5.30 /

-0.14 (-2.57%)

POSH Poshmark
$12.65 /

-0.69 (-5.17%)

PARA Paramount
$37.80 /

-0.315 (-0.83%)

IMRX Immuneering
$6.47 /

-0.36 (-5.27%)

GPS Gap
$14.08 /

-0.56 (-3.83%)

DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

CHKP Check Point
$138.42 /

+0.04 (+0.03%)

BLND Blend Labs
$5.68 /

-0.3 (-5.02%)

WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

04/01/22 Citi
Wynn Resorts upgraded to Buy from Neutral at Citi
03/23/22 Craig-Hallum
Gan Limited price target lowered to $8 from $14 at Craig-Hallum
03/07/22 Argus
DraftKings cut to Hold at Argus on growing Wynn and MGM competition
02/16/22 CBRE
Wynn Resorts price target raised to $130 from $125 at CBRE
DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

04/01/22 Goldman Sachs
Dell Technologies downgraded to Neutral from Conviction Buy at Goldman Sachs
03/31/22 Barclays
Dell Technologies price target lowered to $53 from $54 at Barclays
03/31/22 Morgan Stanley
Dell Technologies downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/22 Evercore ISI
Dell Technologies upgraded to Outperform from In Line at Evercore ISI
IMRX Immuneering
$6.47 /

-0.36 (-5.27%)

03/31/22 Oppenheimer
Immuneering initiated with an Outperform at Oppenheimer
01/07/22 Piper Sandler
Immuneering initiated with an Overweight at Piper Sandler
01/03/22 Guggenheim
Immuneering price target lowered to $30 from $42 at Guggenheim
08/24/21 Morgan Stanley
Immuneering initiated with an Equal Weight at Morgan Stanley
POSH Poshmark
$12.65 /

-0.69 (-5.17%)

03/31/22 Stifel
Poshmark downgraded to Hold from Buy at Stifel
03/23/22 Wedbush
Poshmark price target lowered to $16 from $23 at Wedbush
03/23/22 MKM Partners
Poshmark price target raised to $12 from $10 at MKM Partners
03/23/22 Stifel
Poshmark price target lowered to $19 from $23 at Stifel
VRT Vertiv Holdings
$14.00 /

+0.28 (+2.04%)

04/01/22 JPMorgan
Vertiv upgraded to Overweight on 'compelling' risk/reward at JPMorgan
04/01/22 JPMorgan
Vertiv Holdings upgraded to Overweight from Neutral at JPMorgan
03/31/22 Citi
Vertiv positioned for significantly improved profitability, says Citi
02/24/22 Cowen
Cowen downgrades Vertiv after 'dismal' Q4 performance
BLND Blend Labs
$5.68 /

-0.3 (-5.02%)

04/01/22 Truist
Blend Labs price target lowered to $5.50 from $7.50 at Truist
04/01/22 Canaccord
Canaccord downgrades Blend Labs to Hold, cuts target to $5 from $28
04/01/22 Wells Fargo
Blend Labs downgraded to Equal Weight from Overweight at Wells Fargo
04/01/22 KeyBanc
Blend Labs price target lowered to $6 from $10 at KeyBanc
UPST Upstart
$109.00 /

-4.87 (-4.28%)

03/31/22 Stephens
Stephens 'cautious' on Upstart, starts at Equal Weight
03/31/22 Stephens
Upstart initiated with an Equal Weight at Stephens
03/22/22 Wedbush
Wedbush downgrades Upstart to Underperform, lowers price target to $75
03/22/22 Wedbush
Upstart downgraded to Underperform from Neutral at Wedbush
GPS Gap
$14.08 /

-0.56 (-3.83%)

04/01/22 Barclays
Gap downgraded to sell on heightened risks at Barclays
04/01/22 Barclays
Gap downgraded to Underweight from Equal Weight at Barclays
03/09/22 Daiwa
Gap downgraded to Underperform from Neutral at Daiwa
03/04/22 BMO Capital
Gap price target lowered to $16 from $19 at BMO Capital
TELL Tellurian
$5.30 /

-0.14 (-2.57%)

04/01/22 Credit Suisse
Tellurian upgraded to Outperform from Neutral at Credit Suisse
07/08/21 B. Riley
B. Riley starts Tellurian with Buy on liquefied natural gas growth
07/08/21 B. Riley
Tellurian initiated with a Buy at B. Riley
06/22/21 Roth Capital
Tellurian pipeline could lead to reduced emissions, says Roth Capital
CMA Comerica
$90.42 /

-2.455 (-2.64%)

04/01/22 JPMorgan
Comerica upgraded to Overweight on tailwind from hikes at JPMorgan
04/01/22 Goldman Sachs
Comerica upgraded to Neutral from Sell at Goldman Sachs
04/01/22 JPMorgan
Comerica upgraded to Overweight from Neutral at JPMorgan
03/24/22 Citi
Comerica assumed with a Buy at Citi
CHKP Check Point
$138.42 /

+0.04 (+0.03%)

03/31/22 Summit Insights
Summit Insights starts Check Point at Buy, sees it as 'solid defensive stock'
03/31/22 Summit Insights
Check Point initiated with a Buy at Summit Insights
03/21/22 Piper Sandler
Check Point downgraded to Underweight from Neutral at Piper Sandler
03/17/22 Deutsche Bank
Check Point price target raised to $160 from $154 at Deutsche Bank
PARA Paramount
$37.80 /

-0.315 (-0.83%)

04/01/22 JPMorgan
Paramount reinstated with a Neutral at JPMorgan
03/18/22 UBS
Paramount price target lowered to $29 from $33 at UBS
02/17/22 Barrington
Paramount price target lowered to $34 from $50 at Barrington
AWKNF Awakn Life Sciences
$1.20 /

+ (+0.00%)

04/01/22 Stifel
Awakn Life Sciences initiated with a Speculative Buy at Stifel
02/01/22 H.C. Wainwright
Awakn Life Sciences initiated with a Buy at H.C. Wainwright
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 JonesTrading
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 H.C. Wainwright
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
W Wayfair
$110.75 /

-10.75 (-8.85%)

04/01/22 Needham
Wayfair price target lowered to $150 from $180 at Needham
04/01/22 Barclays
Wayfair downgraded to sell on heightened risks at Barclays
04/01/22 Barclays
Wayfair downgraded to Underweight from Equal Weight at Barclays
03/30/22 Loop Capital
Loop Capital cuts Wayfair to Sell on inflation, rising rate headwinds
WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

W Wayfair
$110.75 /

-10.75 (-8.85%)

VRT Vertiv Holdings
$14.00 /

+0.28 (+2.04%)

UPST Upstart
$109.00 /

-4.87 (-4.28%)

TELL Tellurian
$5.30 /

-0.14 (-2.57%)

SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

POSH Poshmark
$12.65 /

-0.69 (-5.17%)

IMRX Immuneering
$6.47 /

-0.36 (-5.27%)

GPS Gap
$14.08 /

-0.56 (-3.83%)

DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

CMA Comerica
$90.42 /

-2.455 (-2.64%)

CHKP Check Point
$138.42 /

+0.04 (+0.03%)

BLND Blend Labs
$5.68 /

-0.3 (-5.02%)

  • 02
    Nov
  • 04
    Aug
  • 30
    Jul
  • 16
    Jul
  • 16
    Jun
  • 09
    Apr
WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

PARA Paramount
$37.80 /

-0.315 (-0.83%)

DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

CHKP Check Point
$138.42 /

+0.04 (+0.03%)

WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

W Wayfair
$110.75 /

-10.75 (-8.85%)

UPST Upstart
$109.00 /

-4.87 (-4.28%)

TELL Tellurian
$5.30 /

-0.14 (-2.57%)

POSH Poshmark
$12.65 /

-0.69 (-5.17%)

PARA Paramount
$37.80 /

-0.315 (-0.83%)

GPS Gap
$14.08 /

-0.56 (-3.83%)

DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

CMA Comerica
$90.42 /

-2.455 (-2.64%)

CHKP Check Point
$138.42 /

+0.04 (+0.03%)

BLND Blend Labs
$5.68 /

-0.3 (-5.02%)

AWKNF Awakn Life Sciences
$1.20 /

+ (+0.00%)

WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

W Wayfair
$110.75 /

-10.75 (-8.85%)

UPST Upstart
$109.00 /

-4.87 (-4.28%)

TELL Tellurian
$5.30 /

-0.14 (-2.57%)

POSH Poshmark
$12.65 /

-0.69 (-5.17%)

PARA Paramount
$37.80 /

-0.315 (-0.83%)

GPS Gap
$14.08 /

-0.56 (-3.83%)

DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

CMA Comerica
$90.42 /

-2.455 (-2.64%)

BLND Blend Labs
$5.68 /

-0.3 (-5.02%)

Downgrade
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink » 08:56
04/01/22
04/01
08:56
04/01/22
08:56
SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

SVB Leerink analyst Daina…

SVB Leerink analyst Daina Graybosch downgraded Silverback Therapeutics to Market Perform from Outperform with a price target of $1.80, down from $25.00. The downgrade follows the company's decision to discontinue their two leading oncology programs, SBT6050 and SBT6290, given toxicity that limited SBT6050 dose in combination with pembrolizumab and lack of SBT6050 single-agent activity, Graybosch tells investors in a research note.

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

04/01/22 JonesTrading
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 H.C. Wainwright
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/01/22 Stifel
Silverback Therapeutics downgraded to Hold from Buy at Stifel
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

Downgrade
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading » 08:39
04/01/22
04/01
08:39
04/01/22
08:39
SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

JonesTrading analyst…

JonesTrading analyst Soumit Roy downgraded Silverback Therapeutics to Hold from Buy with no price target after the company discontinued development of all of their oncology assets, including lead asset SBT6050, and shifted focus entirely to preclinical asset SBT8230 for chronic HBV. He sees a Hold rating as appropriate until there is more clarity on the path forward and Silverback is closer to clinical data, Roy tells investors.

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 H.C. Wainwright
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/01/22 Stifel
Silverback Therapeutics downgraded to Hold from Buy at Stifel
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

Downgrade
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink » 07:55
04/01/22
04/01
07:55
04/01/22
07:55
SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

SVB Leerink analyst Daina…

SVB Leerink analyst Daina Graybosch downgraded Silverback Therapeutics to Market Perform from Outperform with a $1.80 price target.

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

04/01/22 H.C. Wainwright
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/01/22 Stifel
Silverback Therapeutics downgraded to Hold from Buy at Stifel
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

Downgrade
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright » 06:06
04/01/22
04/01
06:06
04/01/22
06:06
SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White downgraded Silverback Therapeutics to Neutral from Buy without a price target. The company announced it has discontinued the development of SBT6050, its lead product candidate comprised of a TLR8 linker-payload conjugated to a HER2-directed monoclonal antibody targeting Nectin4, White tells investors in a research note. The company has also decided to discontinue the development of SBT6290 due to the likelihood of it having a similar clinical profile to SBT6050, he adds. White cites these moves for the downgrade.

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

04/01/22 Stifel
Silverback Therapeutics downgraded to Hold from Buy at Stifel
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

Downgrade
Silverback Therapeutics downgraded to Hold from Buy at Stifel » 05:25
04/01/22
04/01
05:25
04/01/22
05:25
SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey downgraded Silverback Therapeutics to Hold from Buy with a price target of $6, down from $32. Management's discontinuation of the SBT6050/SBT6290 development programs, a decision predicated on limited single-agent SBT6050 anti-tumor activity observed to date and cytokine-related, dose-limiting toxicities which challenge the pursuit of combinations, "represents a material change" to the investment thesis, Willey tells investors in a research note. The analyst believes SBT8230 still holds promise in hepatitis B virus but says additional visibility into the potential for this asset "will take significant time to manifest."

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

Earnings
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60) » 16:01
03/31/22
03/31
16:01
03/31/22
16:01
SBTX

Silverback Therapeutics

$3.42 /

-0.1 (-2.84%)

"Upon comprehensive…

"Upon comprehensive review of our clinical and preclinical data for our TLR8 oncology programs, we have made the decision to discontinue the development of SBT6050 and SBT6290, and focus our resources on SBT8230 for chronic HBV as well as our ImmunoTAC discovery programs," said Laura Shawver, Ph.D., chief executive officer of Silverback. "We would like to thank the investigators and the staff at each of our sites, and most importantly, the patients who participated in our trial and their families."

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.42 /

-0.1 (-2.84%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
SBTX Silverback Therapeutics
$3.42 /

-0.1 (-2.84%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.